April 2023
TNG908, a brain-penetrant MTA-cooperative PRMT5 inhibitor, is efficacious in preclinical glioblastoma models
April 2023
TNG348 is a potent and selective inhibitor of USP1 for the treatment of BRCA1/2mut and HRD+ cancers
April 2023
TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted solid tumors
February 2023
Ubiquitinated PCNA drives USP1 synthetic lethality in cancer
November 2022
Leveraging CRISPR-Cas9 screening platform for discovery of novel tumor intrinsic phagocytosis modulators
